Le Lézard
Classified in: Health, Science and technology
Subjects: PER, SHM

Mindmed Announces Voting Results for Annual General and Special Meeting

NEW YORK, June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").

Election of Directors

The five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows:

Name of Nominee

Votes For

Votes Withheld

Number of

Percentage of

Number of

Percentage of

Carol A. Vallone





Andreas Krebs





Brigid A. Makes





Robert Barrow





Dr. Miri Halperin Wernli





Appointment of Auditor

At the Meeting, KPMG LLP was appointed as the auditor of the Company for the ensuing year and the directors were authorized to fix the remuneration to be paid to the auditor.

Alteration to the Company's Share Structure

At the Meeting, shareholders approved the alteration to the Company's share structure to eliminate the Multiple Voting Shares of the Company and re-designate the Subordinate Voting Shares as Common Shares of the Company.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: [email protected]
For Investors: [email protected]

SOURCE Mind Medicine (MindMed) Inc.

These press releases may also interest you

at 00:01
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) on June 9, 2023 to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class...

8 jun 2023
Mind Cure Health Inc. (FRA: 6MH) ("Mind Cure", the "Company" or the "Resulting Issuer" following the completion of the Proposed Transaction (as defined below)) and LNG Energy Group Inc. ("LNG Energy") are pleased to provide an update on the...

8 jun 2023
On 8 June 2023, the 2023 Fosun International Investor Open Day was held in Shanghai. It was the first time that Fosun International had held a large-scale offline open day after the pandemic. More than 100 domestic and foreign investor...

8 jun 2023
Elevation Oncology, Inc. , an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an...

8 jun 2023
On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities...

8 jun 2023
The National Health IT Collaborative for the Underserved (NHIT), the first and oldest national non-profit focused on equitable access to health technology for underserved communities and communities of color, celebrated its 15th anniversary today...

News published on and distributed by: